Discover Lead Molecules Against Difficult Targets In 1 Week

Antibody therapeutics have been developed for a host of different diseases, ranging from autoimmune disorders to infectious diseases and cancer. As new therapy approvals steadily increase and the demand for antibody therapies grows, so does the need for technologies that can accelerate the discovery of functional therapeutic antibodies, also known as lead molecules. However, discovering novel lead molecules requires methods to screen and rapidly down-select a diverse panel of antibodies.

Discover Opto^® Plasma B Discovery 4.0. With this kit and workflow you can access broad plasma cell diversity by screening up to 100,000 plasma cells, rapidly down-select lead candidates against difficult targets, and sequence and re-express >1,000 functionally characterized antibodies for less than $100/molecule, in 1 week.